Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Shuffle Sales Brass, Restructure Commissions, Consolidate Antibody Manufacturing

SAN DIEGO (GenomeWeb News) — Invitrogen, hoping to reverse a $130-million third-quarter loss, will make changes to its sales force leadership and restructure its commission policy, CEO Greg Luciersaid yesterday.
Speaking to investors at the JP Morgan Healthcare Conference in San Francisco yesterday, Lucier said Invitrogen will also consolidate its antibody manufacturing process, putting more focus on productivity, Lucier said.
The company is also continuing to review the effectiveness of its sales force, and ways to expand its gross margin.
Notably absent from Lucier’s remarks was talk of planned acquisitions, which the company typically mentions before audiences of investors and equity analysts. Lucier made no mention during the presentation of any upcoming M&A activity, suggesting that after going on a buying spree during the past few years Invitrogen may be taking a more conservative approach on potential acquisitions.
During the past 3-and-a-half years, Invitrogen has acquired 15 companies, which averages out to a little less than five buys a year, Lucier said.
The company has described difficulties integrating past acquisitions such as Zymed, Biosource, and Caltag, and has identified these units as key reasons for its flagging financials over the past few quarters.
“In 2006, with any company that did as much as we’ve done in the last 3-and-a-half years, we clearly stumbled,” Lucier said. “We also did a number of integrations with all those companies that we acquired over the last few years. In 2006, the real crunch in terms of heavy lifting of closing plants, moving production lines, and consolidating them into a few of the remaining campuses took place.”

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.